2025 annual meeting
New Frontiers of Bispecific Antibodies, Antibody Drug Conjugates and Beyond
May 10, 2025, 8:30 a.m. US/Eastern
In person at Boston Marriott Cambridge
Register Now
May 10, 2025, 8:30 a.m. US/Eastern
In person at Boston Marriott Cambridge
Register Now
Welcome to the 2025 Annual Conference of the Chinese Antibody Society (CAS)! We are thrilled to host this year's event at the Boston Marriott Cambridge in Cambridge, MA, on Saturday, May 10, 2025.
With the theme "New Frontiers in Bispecific Antibodies, Antibody-Drug Conjugates, and Beyond," this conference will showcase cutting-edge advancements and groundbreaking innovations in antibody research and therapeutic development. Join us for a day of insightful discussions, expert-led presentations, and valuable networking opportunities with leaders in the field.
Sponsorship Opportunities
The 2025 Annual Conference Sponsorship Drive is now underway, offering exclusive Title and Premium sponsorship opportunities, each with distinct benefits designed to maximize visibility and engagement.
This year, we are excited to introduce six exclusive naming opportunities—Dinner, Lunch, Name Badges, WiFi, Coffee Breaks, and Posters—providing sponsors with a unique way to enhance their brand recognition. Title sponsors will receive premier recognition, including exclusive naming rights, along with all the benefits of the Premium sponsorship category.
For more details or to secure your sponsorship, please contact us at sponsor@chineseantibody.org.
Conference Details
• Date: Saturday, May 10, 2025
• Location: Boston Marriott Cambridge, 50 Broadway, Cambridge, MA 02142, USA
Registration Information:
• Academia (students, post-docs, PI, etc.) – Conference Only: $15 | Conference + Dinner: $100
• CAS Members – Conference Only: $30 | Conference + Dinner: $100
• Non-Members – Conference Only: $50 | Conference + Dinner: $150
Chinese Antibody Society members will enjoy discount on registration fees. To become a member, please visit https://chineseantibody.org.
Please be aware that while we do accommodate on-site registrations, the fees for registering on-site will differ from those for pre-registrations. We recommend registering early due to limited seating for both the conference and the dinner event. Registration will close automatically once capacity is reached.
Parking Information
The conference venue (Boston Marriott Cambridge) offers a discounted parking rate of $10 for the entire event at the hotel Green Garage. Please ask for the parking voucher at the CAS registration desk.
More Information
Conference brochure will be available soon. Stay tuned!
Join Us
We cordially invite you to the 2025 Annual CAS Conference. Stay tuned for updates on the CAS official website, LinkedIn, and our WeChat account.
Welcome to Submit Your Abstract! 2025 Chinese Antibody Society Annual Conference Poster Session
The Chinese Antibody Society's 2025 annual conference will be held on May 10th in Boston Marriott Cambridge. Over the years, the annual conference has become a significant event for industry professionals to gather and exchange ideas. In order to enhance peer-to-peer communication, we prepared to continue the Poster Presentation session at this year's annual conference. Due to the large membership and broad professional coverage in our society, the Poster Presentation will be an excellent platform for both the industry and academia to showcase their achievements.
The society places high importance on this initiative and has formed a distinguished panel of judges. The panel including Prof. Mi Deng from Peking University and Prof. Xuyao Zhang from Fudan University. We welcome contributions across a broad spectrum of topics within the field of therapeutic antibodies. Submissions can include, but are not limited to, innovations in modalities, breakthrough technologies in the discovery, development, and manufacturing of antibody drugs, as well as the latest advancements in production processes and clinical updates.
Here are some relevant details and requirements:
●The abstract title and main text should be in English, within 500 words.
●All poster abstract submissions will undergo review and scoring process, and the committee will select top 3 abstracts for oral presentation, and 20 abstracts for poster presentations at the annual meeting. Authors of these selected abstracts will have the opportunity to add images and data for exhibiting at the meeting.
●The first or corresponding authors of the top three abstracts who also deliver a 10-minute on-site presentation will receive an additional travel award ranging from $500 to $1000.
●Each poster award winner can bring three attendees to the annual meeting in person, with waived registration fees.
Abstract submissions can be made at www.casconferenceposter.org, and we will accept abstracts until April 11th. You can stay updated on the submission system through our WeChat posts or LinkedIn account. We welcome all submissions! If you have any questions, please feel free to ask in any of the association's member groups or professional discussion groups, or contact us via email at submission@chineseantibody.org.
Hover above speaker cards to read bio
Janine Schuurman
President, The Antibody Society
Andre Teixeira
Senior Director, Head of Antibody Platform, Institute for Protein Innovation
Benny Yang
CSO, Biocytogen Pharmaceuticals (Beijing) Co., Ltd
Bob Lutz
CSO, Iksuda Therapeutics
Donghui Ma
CEO, DIMA Biotechnology
Hongtao Lu
Co-Founder & CSO, Elpiscience Biopharmaceuticals
Jie Chen
CTO, GV20 Therapeutics
Nimish Gera
Head of Biologics, VP, Mythic Therapeutics
Paolo Tarantino
Clinical Research Fellow, Dana-Farber Cancer Institute
Ronnie Wei
Head of Biologics Discovery and Development, ModeX Therapeutics
Rakesh Dixit
President & CEO, Regio Biosciences
Xin Zhou
Assistant Professor, Harvard University
Xinyan Zhao
CEO, Adept Therapeutics Inc.
Zhiqiang An
Professor, The University of Texas Health Science Center at Houston
Manhee Suh
CTO, Kactus Biosystems
Starts at 05/10/2025 8:30 a.m. US/Eastern
Hover to view abstract
05/10/2025 8 a.m. US/Eastern
Registration
Chinese Antibody Society, TBD, TBD
05/10/2025 9 a.m. US/Eastern
Opening remarks
Zhiqiang An, Professor, The University of Texas Health Science Center at Houston
05/10/2025 9:05 a.m. US/Eastern
Announcements and overview of Chinese Antibody Society
Peng Lin, President-elect, Chinese Antibody Society
05/10/2025 9:10 a.m. US/Eastern
Mining Antibody Biology for Novel Functionalities and Therapeutic Antibody Development
Janine Schuurman, President, The Antibody Society
05/10/2025 9:40 a.m. US/Eastern
Unlocking the potential of bi-specific myeloid engagers (BiME) in solid tumor immunotherapy
Hongtao Lu, Co-Founder & CSO, Elpiscience Biopharmaceuticals
05/10/2025 10:10 a.m. US/Eastern
Coffee Break
Chinese Antibody Society, TBD, TBD
05/10/2025 11:10 a.m. US/Eastern
Next-Gen Immunotherapy: Engineering Multispecific Antibodies Against Tumor Resistance
Ronnie Wei, Head of Biologics Discovery and Development, ModeX Therapeutics
05/10/2025 11:40 a.m. US/Eastern
Industry Trending of Antibody-Drug Conjugates CMC Development and GV20 ADC development Strategy
Jie Chen, CTO, GV20 Therapeutics
05/10/2025 12:10 p.m. US/Eastern
Advancing Tumor Immunotherapy: Next-Gen MHC and Transmembrane Protein Platforms for High-Impact Discovery
Manhee Suh, CTO, Kactus Biosystems
05/10/2025 12:30 p.m. US/Eastern
Lunch
Chinese Antibody Society, TBD, TBD
05/10/2025 1:30 p.m. US/Eastern
Poster Presentation & Best Poster Awards
Chinese Antibody Society, TBD, TBD
05/10/2025 2:05 p.m. US/Eastern
Transferrin receptor targeting chimeras (TransTACs), a heterobispecific antibody modality for membrane protein degradation
Xin Zhou, Assistant Professor, Harvard University
05/10/2025 2:35 p.m. US/Eastern
End-to-End Discovery: Antibodies, Nanobodies, Biparatopics, and AI-Driven Insights
Andre Teixeira, Senior Director, Head of Antibody Platform, Institute for Protein Innovation
05/10/2025 3:05 p.m. US/Eastern
Coffee Break
Chinese Antibody Society, TBD, TBD
05/10/2025 3:50 p.m. US/Eastern
Therapeutic mAb discovery for multi-pass transmembrane protein targets
Donghui Ma, CEO, DIMA Biotechnology
05/10/2025 4:20 p.m. US/Eastern
MYTX-011: an anti-cMET antibody-drug conjugate designed for enhanced payload delivery to cMET expressing tumor cells
Nimish Gera, Head of Biologics, VP, Mythic Therapeutics
05/10/2025 4:50 p.m. US/Eastern
ADC panel discussion: Challenges and opportunities of next generation ADCs for cancers and beyond.
Rakesh Dixit, President & CEO, Regio Biosciences
05/10/2025 5:35 p.m. US/Eastern
Closing remarks
Zhiqiang An, Professor, The University of Texas Health Science Center at Houston
05/10/2025 5:45 p.m. US/Eastern
Social Hour
Chinese Antibody Society, TBD, TBD
05/10/2025 6:45 p.m. US/Eastern
Dinner tickets required
Chinese Antibody Society, TBD, TBD
Social Hour
Chinese Antibody Society, TBD, TBD
Social Hour